查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081452

抗癌藥物市場：2026-2032年全球市場預測（依藥物類別、給藥途徑、分子類型、適應症、最終用戶和分銷管道分類）

Oncology Drugs Market by Drug Class, Route of Administration, Molecule Type, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗癌藥物市場將成長至 3,761 億美元，複合年成長率為 7.55%。

主要市場統計數據
基準年 2025 2258.6億美元
預計年份：2026年 2423.2億美元
預測年份 2032 3761億美元
複合年成長率 (%) 7.55%

癌症發生率的上升、精準醫療的進步以及免疫腫瘤學、標靶治療、抗體藥物複合體、放射性藥物和細胞基因療法的快速發展，正在重塑抗癌藥物市場。根據國際癌症研究機構（IARC）發布的《2022年全球癌症研究展望》（GLOBOCAN 2022）估計，全球每年新增癌症病例約2000萬例，癌症相關死亡病例約970萬例，這顯示臨床上對有效癌症治療的需求依然旺盛。

市場需求日益集中在能夠提高存活率、降低毒性以及實現基於分子診斷的治療方案。美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 的核准情況表明，基於生物標記的適應症、腫瘤聚集療法以及存在高度嚴重的嚴重癌症的快速核准流程正持續推進。對於行業領導者而言，如今的競爭優勢在於循證醫學、伴隨診斷、准入策略、生產韌性以及在全球腫瘤治療領域的全生命週期管理。

腫瘤藥物領域的變革性變化

癌症治療格局正從廣譜細胞毒性療法轉向更個人化、以聯合治療為基礎的治療模式。免疫查核點抑制劑、激酶抑制劑、PARP抑制劑、雙特異性抗體、CAR-T細胞療法、抗體藥物複合體和放射性配體療法正在拓展骨髓惡性腫瘤和固體癌的治療選擇。

人工智慧在癌症治療藥物領域的累積影響

人工智慧正對癌症治療的各個領域產生累積影響，從藥物發現和臨床開發到醫學事務和商業化。人工智慧模型被用於分析基因組數據、病理影像、放射影像、電子健康記錄和臨床試驗資料集，從而有助於標靶識別、患者分層、治療反應預測以及提高臨床試驗的可行性。

癌症藥物市場的關鍵區域洞察

北美憑藉其先進的臨床試驗基礎設施、高生物標記檢測普及率、對生物醫學研究的大量投入以及美國促進嚴重疾病快速研發的監管政策，持續引領著腫瘤學創新中心的發展。美國廣泛應用新型免疫療法、標靶治療和先進細胞療法，從而帶動了全部區域需求。同時，加拿大則專注於醫療技術評估、全國範圍的審查流程以及影響患者獲得治療時間的省級報銷機制。

針對特定族群的抗癌藥物策略的關鍵見解

在東協地區，由於癌症篩檢、專科醫院、病理檢測能力和國家健保報銷體系的擴展，對抗癌藥物的需求不斷成長，但高所得與中低收入成員國在藥物取得方面仍然存在差距。擁有健全的全民健康覆蓋（UHC）和三級癌症診療網路的國家更有利於引入基於生物標記的療法，而其他國家則繼續優先考慮基本的癌症治療，擴大診斷能力並確保治療費用可負擔性。海灣合作理事會（GCC）成員國正在投資癌症中心、基因組檢測、專科醫院網路和國家癌症戰略，這創造了對創新抗癌藥物的需求，同時也優先考慮採購效率、本地醫療衛生系統優先事項和人力資源開發。

主要國家抗癌藥物的發展趨勢

美國憑藉積極的臨床試驗活動、頻繁的抗癌藥物法規核准、學術癌症中心、先進的分子檢測技術以及在合格的患者群體中廣泛應用免疫療法、標靶治療和細胞療法，在全球癌症藥物商業化領域處於領先地位。加拿大則透過國家和省級審查體系，優先考慮基於實證醫學的報銷。同時，墨西哥和巴西代表拉丁美洲的關鍵機遇，其發展得益於公共部門的醫療服務、私人保險覆蓋範圍、不斷擴大的癌症護理網路以及在及時診斷和生物標記檢測方面持續存在的差距。

為癌症治療行業的領導者提供的實用建議

產業領導者應優先考慮以生物標記主導的研發計劃，從早期階段就將臨床試驗設計、伴隨診斷、監管申報和市場進入等方面的證據聯繫起來。抗癌藥物組合的評估不僅應考慮腫瘤類型，還應考慮作用機制、抗藥性機制、定序潛力、耐受性、合併用藥策略以及滿足明確未滿足醫療需求的能力。

癌症藥物市場分析的調查方法

本執行摘要是基於可靠的公共資源進行的二手研究，包括世界衛生組織 (WHO)、國際癌症研究機構 (IARC) GLOBOCAN資料庫、美國食品藥物管理局(FDA)、歐洲藥品管理局 (EMA)、各國癌症機構、同行評審的癌症文獻、臨床試驗註冊庫、治療指南和已發布的監管資訊來源。分析內容涵蓋疾病負擔、監管趨勢、治療創新、區域可近性趨勢、診斷基礎設施發展和醫療保健基礎設施指標。

結論：腫瘤藥物的戰略展望

抗癌藥物市場正進入一個更精準、數據密集且對藥物可及性更為敏感的階段。儘管科學進步不斷拓展治療選擇，涵蓋免疫療法、標靶治療、抗體藥物複合體、放射性藥物和細胞療法，但成功越來越依賴於展現差異化的臨床價值、開發診斷工具以及確保在不同的醫療保健系統中及時供應。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：抗癌藥物市場：依藥物類別分類

  • 化療藥物
    • 烷化劑
    • 抗代謝物
  • 荷爾蒙療法藥物
  • 免疫治療藥物
    • CAR-T細胞療法
    • 查核點抑制劑
      • CTLA-4抑制劑
      • PD-1/PD-L1抑制劑
  • 分子標靶療法
    • 單株抗體
      • 嵌合體
      • 人性化
    • 小分子抑制劑
      • 週期蛋白依賴型激酶抑制劑
      • 蛋白酪氨酸激酶抑制劑

第8章：抗癌藥物市場：依給藥途徑分類

  • 注射藥物
    • 肌肉內部
    • 靜脈
    • 皮下
  • 口服

第9章：抗癌藥物市場：依分子類型分類

  • 生物製劑
    • 單株抗體
    • 疫苗
  • 低分子化合物

第10章：抗癌藥物市場：依適應症分類

  • 血癌
    • 白血病
      • 急性骨髓性白血病
      • 慢性淋巴性白血病
    • 淋巴瘤
      • 何傑金氏淋巴瘤
      • 非何傑金氏淋巴瘤
  • 乳癌
  • 結腸癌
  • 肺癌
  • 攝護腺癌

第11章：抗癌藥物市場：依最終用戶分類

  • 醫院
  • 研究機構
  • 專科診所

第12章：抗癌藥物市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：抗癌藥物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：抗癌藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：抗癌藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Ltd.
  • AbbVie Inc.
  • Agenus Inc.
  • Amgen Inc.
  • Apres-demain SA
  • Aspen Pharmacare Holdings Limited
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Inc.
  • Biovista Inc.
  • Blueprint Medicines Corporation
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Cellectar Biosciences, Inc.
  • Cipla Limited
  • Dr Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hofmann-La Roche Ltd.
  • Genentech, Inc
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Healthcare Limited
  • Ipsen SA
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Merck KGaA
  • MSN Laboratories
  • Natco Pharma Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Puma Biotechnology, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Sutro Biopharma, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Vascular Biogenics Ltd.
  • Viatris Inc.
Product Code: MRR-434CCDA05255

The Oncology Drugs Market is projected to grow by USD 376.10 billion at a CAGR of 7.55% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 225.86 billion
Estimated Year [2026] USD 242.32 billion
Forecast Year [2032] USD 376.10 billion
CAGR (%) 7.55%

The oncology drugs market is being reshaped by rising cancer incidence, precision medicine, and the rapid expansion of immuno-oncology, targeted therapy, antibody-drug conjugates, radiopharmaceuticals, and cell and gene therapies. According to the International Agency for Research on Cancer's GLOBOCAN 2022 estimates, there were approximately 20 million new cancer cases and 9.7 million cancer deaths worldwide, underscoring the sustained clinical need for effective cancer therapeutics.

Demand is increasingly concentrated around therapies that improve survival, reduce toxicity, and align treatment with molecular diagnostics. Regulatory approvals from the U.S. Food and Drug Administration and the European Medicines Agency show continued momentum for biomarker-directed indications, tumor-agnostic therapies, and expedited pathways for serious cancers with unmet need. For industry leaders, competitive advantage now depends on evidence generation, companion diagnostics, access strategy, manufacturing resilience, and lifecycle management across global oncology care settings.

Transformative Shifts in the Oncology Drugs Landscape

The oncology therapeutics landscape is moving from broad cytotoxic regimens toward more personalized, combination-based treatment models. Immune checkpoint inhibitors, kinase inhibitors, PARP inhibitors, bispecific antibodies, CAR-T cell therapies, antibody-drug conjugates, and radioligand therapies are expanding treatment options across hematologic malignancies and solid tumors.

A major transformative shift is the integration of diagnostics into drug development and clinical decision-making. Biomarkers such as PD-L1, MSI-H/dMMR, EGFR, ALK, HER2, BRCA, BRAF, NTRK, and KRAS G12C increasingly determine eligibility, sequencing, and expected response. At the same time, payers and health systems are demanding real-world evidence, comparative effectiveness data, patient-reported outcomes, and outcomes-based value narratives as oncology drug costs rise and treatment pathways become more complex.

Cumulative Impact of Artificial Intelligence in Oncology Drugs

Artificial intelligence is having a cumulative impact across oncology drug discovery, clinical development, medical affairs, and commercialization. AI-enabled models are used to analyze genomics, pathology images, radiology scans, electronic health records, and clinical trial datasets to identify targets, stratify patients, predict response, and improve trial feasibility.

The strongest near-term value is emerging in patient matching, adaptive trial design, pharmacovigilance signal detection, biomarker discovery, synthetic control arm development, and evidence synthesis from real-world datasets. However, adoption depends on validated datasets, transparent model governance, regulatory alignment, cybersecurity safeguards, bias mitigation, and clinical usability. In oncology, where treatment decisions can be life-critical, AI must augment expert judgment rather than replace evidence-based medical practice.

Key Regional Insights Across Oncology Drug Markets

North America remains a central hub for oncology drug innovation, supported by advanced clinical trial infrastructure, high biomarker testing adoption, substantial biomedical research investment, and U.S. regulatory programs that support expedited development for serious diseases. The United States anchors regional demand through broad availability of novel immunotherapies, targeted therapies, and advanced cellular therapies, while Canada emphasizes health technology assessment, pan-Canadian review processes, and provincial reimbursement pathways that shape access timelines.

Europe combines strong scientific capabilities with a structured regulatory and reimbursement environment shaped by the European Medicines Agency, national health technology assessment bodies, and cross-border cancer policy initiatives. The region's oncology drug landscape is influenced by centralized medicine evaluation, national pricing negotiations, and growing emphasis on equitable cancer care under European cancer policy frameworks. Asia-Pacific is gaining importance through China's expanding biopharmaceutical sector, Japan's mature oncology treatment environment, South Korea's clinical research ecosystem, India's high patient volumes and biosimilar capabilities, and Australia's advanced regulatory and trial capabilities.

Latin America presents meaningful unmet need, with Brazil and Mexico serving as key access and commercialization markets, although reimbursement variability, out-of-pocket burden, and diagnostic infrastructure gaps remain important constraints. The Middle East is increasing investment in oncology centers, genomic medicine, and specialty care, particularly in Gulf countries where national health transformation programs are strengthening cancer services. Africa faces the largest access challenges, including late diagnosis, limited oncology workforce, constrained pathology and radiotherapy capacity, and restricted availability of advanced therapies, making affordability, early detection, and essential cancer medicines critical priorities.

Key Group Insights for Oncology Drug Strategy

Within ASEAN, oncology drug demand is increasing as cancer screening, specialty hospitals, pathology capacity, and national reimbursement schemes expand, but access remains uneven across high-income and lower-middle-income member states. Countries with stronger universal health coverage and tertiary cancer networks are better positioned to adopt biomarker-driven therapies, while others continue to prioritize essential cancer medicines, diagnostic scale-up, and affordability. The GCC is investing in cancer centers, genomic testing, specialty hospital networks, and national cancer strategies, creating demand for innovative oncology drugs while emphasizing procurement efficiency, local health system priorities, and workforce development.

The European Union remains influential through centralized medicine evaluation, pharmacovigilance standards, joint clinical assessment under evolving health technology assessment rules, and policy initiatives tied to Europe's Beating Cancer Plan. These mechanisms are reinforcing evidence expectations for oncology drugs, including comparative clinical benefit, quality-of-life outcomes, and real-world effectiveness. BRICS markets are strategically important because they combine large patient populations, growing domestic manufacturing capacity, expanding biosimilar use, and increasing participation in global oncology trials, although affordability, regional access variation, and reimbursement complexity differ widely across member countries.

G7 countries remain the most commercially significant group for premium oncology innovation due to mature reimbursement systems, strong academic oncology networks, advanced clinical trial infrastructure, and high adoption of biomarker-driven care. NATO countries overlap heavily with advanced North American and European markets, where medicine security, resilient supply chains, cybersecurity, and protection of critical health infrastructure are becoming increasingly relevant to oncology drug availability, especially for biologics, radiopharmaceuticals, and complex personalized therapies.

Key Country Insights in Oncology Drugs

The United States leads global oncology commercialization through high clinical trial activity, frequent oncology regulatory approvals, academic cancer centers, advanced molecular testing, and broad use of immunotherapy, targeted therapy, and cellular therapy in eligible populations. Canada prioritizes evidence-based reimbursement through national and provincial review structures, while Mexico and Brazil represent major Latin American opportunities shaped by public-sector access, private insurance coverage, expanding oncology networks, and persistent disparities in timely diagnosis and biomarker testing.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong oncology expertise with national reimbursement assessment and established specialist care pathways, while Germany's early access and benefit assessment pathway remains especially important for launch planning. The United Kingdom continues to emphasize health technology assessment and managed access mechanisms, France applies structured clinical benefit evaluation, and Italy and Spain balance national assessment with regional implementation. Russia remains a complex oncology market influenced by localization requirements, procurement structures, regulatory considerations, and geopolitical constraints that affect access and supply continuity.

China has become a major force in oncology research and development, clinical trials, and domestic biologics innovation, supported by regulatory reforms, expanding hospital capacity, and rising use of targeted therapies and immuno-oncology in specialist centers. India offers large patient volumes, deep generic and biosimilar manufacturing capabilities, and growing oncology service capacity, though affordability and uneven diagnostic access remain central. Japan maintains strong uptake of innovative oncology drugs under a mature regulatory and reimbursement system, South Korea is a leading clinical research and biopharma innovation hub with advanced hospital networks, and Australia supports high-quality trials, genomic medicine initiatives, and early adoption through robust regulatory oversight.

Actionable Recommendations for Oncology Industry Leaders

Industry leaders should prioritize biomarker-driven development plans that connect clinical trial design, companion diagnostics, regulatory submissions, and market access evidence from the earliest stages. Oncology drug portfolios should be evaluated not only by tumor type but also by mechanism of action, resistance biology, sequencing potential, tolerability, combination strategy, and ability to address clearly defined unmet need.

Organizations should strengthen real-world evidence capabilities, diversify clinical trial recruitment, and build access models that address affordability across mature and emerging markets. Supply chain resilience is essential for biologics, radiopharmaceuticals, and cell therapies, where cold chain reliability, isotope availability, manufacturing slots, quality systems, and site certification can directly affect patient access. Leaders should also align medical education, diagnostic partnerships, and value communication to ensure that eligible patients can be identified and treated appropriately.

Research Methodology for Oncology Drug Market Analysis

This executive summary is built on secondary research from validated public sources, including the World Health Organization, the International Agency for Research on Cancer's GLOBOCAN database, the U.S. Food and Drug Administration, the European Medicines Agency, national cancer agencies, peer-reviewed oncology literature, clinical trial registries, treatment guidelines, and public regulatory documents. The analysis evaluates disease burden, regulatory trends, therapeutic innovation, regional access dynamics, diagnostic readiness, and healthcare infrastructure indicators.

Insights were synthesized using a structured market intelligence framework that compares clinical evidence, treatment pathways, approval activity, reimbursement considerations, biomarker adoption, manufacturing requirements, and geographic adoption patterns. Emphasis was placed on verifiable information and directional conclusions supported by recognized oncology data sources rather than speculative projections, market sizing, or forecasting.

Conclusion: Strategic Outlook for Oncology Drugs

The oncology drugs market is entering a more precise, data-intensive, and access-sensitive phase. Scientific progress is expanding treatment options across immunotherapy, targeted therapy, antibody-drug conjugates, radiopharmaceuticals, and cell-based therapies, but success increasingly depends on proving differentiated clinical value, enabling diagnostics, and ensuring timely availability across diverse healthcare systems.

Organizations that combine strong research productivity with biomarker strategy, AI-enabled evidence generation, regulatory discipline, manufacturing reliability, and equitable access planning will be best positioned to lead in the next phase of oncology therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Oncology Drugs Market, by Drug Class

  • 7.1. Chemotherapy Agents
    • 7.1.1. Alkylating Agents
    • 7.1.2. Antimetabolites
  • 7.2. Hormonal Therapy Agents
  • 7.3. Immunotherapy Agents
    • 7.3.1. CAR T-Cell Therapy
    • 7.3.2. Checkpoint Inhibitors
      • 7.3.2.1. CTLA-4 Inhibitors
      • 7.3.2.2. PD-1/PD-L1 Inhibitors
  • 7.4. Targeted Therapy Agents
    • 7.4.1. Monoclonal Antibodies
      • 7.4.1.1. Chimeric
      • 7.4.1.2. Humanized
    • 7.4.2. Small Molecule Inhibitors
      • 7.4.2.1. Cyclin-Dependent Kinase Inhibitors
      • 7.4.2.2. Tyrosine Kinase Inhibitors

8. Oncology Drugs Market, by Route of Administration

  • 8.1. Injectable
    • 8.1.1. Intramuscular
    • 8.1.2. Intravenous
    • 8.1.3. Subcutaneous
  • 8.2. Oral

9. Oncology Drugs Market, by Molecule Type

  • 9.1. Biologics
    • 9.1.1. Monoclonal Antibodies
    • 9.1.2. Vaccines
  • 9.2. Small Molecules

10. Oncology Drugs Market, by Indication

  • 10.1. Blood Cancer
    • 10.1.1. Leukemia
      • 10.1.1.1. Acute Myeloid Leukemia
      • 10.1.1.2. Chronic Lymphocytic Leukemia
    • 10.1.2. Lymphoma
      • 10.1.2.1. Hodgkin Lymphoma
      • 10.1.2.2. Non-Hodgkin Lymphoma
  • 10.2. Breast Cancer
  • 10.3. Colorectal Cancer
  • 10.4. Lung Cancer
  • 10.5. Prostate Cancer

11. Oncology Drugs Market, by End User

  • 11.1. Hospitals
  • 11.2. Research Institutes
  • 11.3. Specialty Clinics

12. Oncology Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Oncology Drugs Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Oncology Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oncology Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Ltd.
  • 17.2. AbbVie Inc.
  • 17.3. Agenus Inc.
  • 17.4. Amgen Inc.
  • 17.5. Apres-demain SA
  • 17.6. Aspen Pharmacare Holdings Limited
  • 17.7. Astellas Pharma Inc.
  • 17.8. AstraZeneca PLC
  • 17.9. Bayer AG
  • 17.10. BeiGene, Inc.
  • 17.11. Biovista Inc.
  • 17.12. Blueprint Medicines Corporation
  • 17.13. Bristol-Myers Squibb Company
  • 17.14. C.H. Boehringer Sohn AG & Co. KG
  • 17.15. Cellectar Biosciences, Inc.
  • 17.16. Cipla Limited
  • 17.17. Dr Reddy's Laboratories Ltd.
  • 17.18. Eisai Co., Ltd.
  • 17.19. Eli Lilly and Company
  • 17.20. Exelixis, Inc.
  • 17.21. F. Hofmann-La Roche Ltd.
  • 17.22. Genentech, Inc
  • 17.23. GlaxoSmithKline PLC
  • 17.24. Glenmark Pharmaceuticals Ltd.
  • 17.25. Hetero Healthcare Limited
  • 17.26. Ipsen SA
  • 17.27. Janssen Pharmaceuticals, Inc.
  • 17.28. Johnson & Johnson Services, Inc.
  • 17.29. Lupin Limited
  • 17.30. Merck & Co., Inc.
  • 17.31. Merck KGaA
  • 17.32. MSN Laboratories
  • 17.33. Natco Pharma Ltd.
  • 17.34. Novartis AG
  • 17.35. Pfizer Inc.
  • 17.36. Puma Biotechnology, Inc.
  • 17.37. Sanofi S.A.
  • 17.38. Sun Pharmaceutical Industries Ltd
  • 17.39. Sutro Biopharma, Inc.
  • 17.40. Takeda Pharmaceutical Company Limited
  • 17.41. Teva Pharmaceutical Industries Ltd
  • 17.42. Vascular Biogenics Ltd.
  • 17.43. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLOGY DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ONCOLOGY DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ONCOLOGY DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ONCOLOGY DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHEMOTHERAPY AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMETABOLITES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMETABOLITES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMETABOLITES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HORMONAL THERAPY AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HORMONAL THERAPY AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HORMONAL THERAPY AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNOTHERAPY AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNOTHERAPY AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNOTHERAPY AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PD-1/PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PD-1/PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PD-1/PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TARGETED THERAPY AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TARGETED THERAPY AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TARGETED THERAPY AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHIMERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHIMERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHIMERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMANIZED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMANIZED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMANIZED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SMALL MOLECULE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SMALL MOLECULE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SMALL MOLECULE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CYCLIN-DEPENDENT KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CYCLIN-DEPENDENT KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CYCLIN-DEPENDENT KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOOD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ACUTE MYELOID LEUKEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ACUTE MYELOID LEUKEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ACUTE MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HODGKIN LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HODGKIN LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HODGKIN LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NON-HODGKIN LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NON-HODGKIN LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NON-HODGKIN LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. GCC ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. GCC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 264. GCC ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 265. GCC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 266. GCC ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 267. GCC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 268. GCC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 269. GCC ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 270. GCC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 271. GCC ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 272. GCC ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. GCC ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 274. GCC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 275. GCC ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 276. GCC ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 277. GCC ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 278. GCC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. GCC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 316. G7 ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. G7 ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 318. G7 ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 319. G7 ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 320. G7 ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 321. G7 ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 322. G7 ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 323. G7 ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 324. G7 ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 325. G7 ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 326. G7 ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. G7 ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 328. G7 ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 329. G7 ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 330. G7 ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 331. G7 ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 332. G7 ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 333. G7 ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 334. NATO ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 335. NATO ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 336. NATO ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 337. NATO ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 338. NATO ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 339. NATO ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 340. NATO ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 341. NATO ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 342. NATO ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 343. NATO ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 344. NATO ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. NATO ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 346. NATO ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 347. NATO ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 348. NATO ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 349. NATO ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 350. NATO ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 351. NATO ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 352. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 353. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 354. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 355. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 356. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 357. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 358. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 359. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 360. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 361. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 362. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 363. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 364. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 365. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 366. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 367. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 368. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 369. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 370. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 371. CANADA ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 372. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 20